• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exagen Inc. - Common Stock (NQ:XGN)

7.280 +0.340 (+4.90%)
Streaming Delayed Price Updated: 11:01 AM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 265,678
Open 7.300
Bid (Size) 7.260 (4)
Ask (Size) 7.300 (3)
Prev. Close 6.940
Today's Range 7.220 - 7.400
52wk Range 1.780 - 7.950
Shares Outstanding 16,126,784
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Exagen Inc. Appoints Chas McKhann to Board of Directors
July 17, 2025
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
July 15, 2025
From Exagen Inc.
Via GlobeNewswire

Performance

YTD
+135.6%
+135.6%
1 Month
+4.4%
+4.4%
3 Month
+50.4%
+50.4%
6 Month
+81.5%
+81.5%
1 Year
+279.2%
+279.2%

More News

Read More
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
June 23, 2025
From Exagen Inc.
Via GlobeNewswire
Earnings Scheduled For May 5, 2025
May 05, 2025
Via Benzinga
Earnings Scheduled For November 12, 2024
November 12, 2024
Via Benzinga
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
May 09, 2025
From Exagen Inc.
Via GlobeNewswire
Top movers in Thursday's pre-market session
May 08, 2025
Via Chartmill
Exagen Inc. Prices Public Offering of Common Stock
May 08, 2025
From Exagen Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
May 08, 2025
Via Benzinga
Get insights into the top gainers and losers of Wednesday's after-hours session.
May 07, 2025
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
May 07, 2025
Via Benzinga
Exagen Inc. Announces Proposed Public Offering of Common Stock
May 07, 2025
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
May 05, 2025
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
April 28, 2025
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
April 21, 2025
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
March 11, 2025
From Exagen Inc.
Via GlobeNewswire
Earnings Scheduled For March 11, 2025
March 11, 2025
Via Benzinga
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
February 25, 2025
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Participate in Upcoming Investor Conferences
February 04, 2025
From Exagen Inc.
Via GlobeNewswire
Tuesday's session: top gainers and losers
February 04, 2025
Via Chartmill
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
January 12, 2025
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
December 12, 2024
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
November 14, 2024
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
November 13, 2024
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Reports Third Quarter 2024 Results
November 12, 2024
From Exagen Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Exagen Inc. - Common Stock publicly traded?
Yes, Exagen Inc. - Common Stock is publicly traded.
What exchange does Exagen Inc. - Common Stock trade on?
Exagen Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Exagen Inc. - Common Stock?
The ticker symbol for Exagen Inc. - Common Stock is XGN on the Nasdaq Stock Market
What is the current price of Exagen Inc. - Common Stock?
The current price of Exagen Inc. - Common Stock is 7.280
When was Exagen Inc. - Common Stock last traded?
The last trade of Exagen Inc. - Common Stock was at 07/23/25 11:01 AM ET
What is the market capitalization of Exagen Inc. - Common Stock?
The market capitalization of Exagen Inc. - Common Stock is 117.40M
How many shares of Exagen Inc. - Common Stock are outstanding?
Exagen Inc. - Common Stock has 117M shares outstanding.
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap